Given SCD1’s crucial role in dampening microglial activation and limiting effector T cell activation by enhancing Treg formation, its inhibition could offer a promising therapeutic strategy to reduce neuroinflammation in DLB and potentially other inflammatory synucleinopathies. Here, SCD is linked to synucleinopathy.